Skip to main content
Clinical Trials/NCT06325852
NCT06325852RecruitingNot Applicable

Directional Bilateral Thalamic Patterned Stimulation in Individuals with Essential Tremor

Alfonso Fasano1 site in 1 country15 target enrollmentStarted: July 16, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
15
Locations
1
Primary Endpoint
Tremor analysis (meter per second squared)

Study Overview

Brief Summary

Population Size and Eligible Patients: The investigators aim to recruit 5 to 10 patients with tremors who have previously undergone Ventral Intermedius Deep Brain Stimulation (VIM-DBS) treatment but have experienced early or late loss of benefits. Additionally, the investigators will enroll ten patients with essential tremor who require VIM-DBS surgery. These individuals will undergo bilateral implantation of Boston Scientific Genus Implantable Pulse Generator (IPG) devices, connected to Boston Scientific Cartesia™ 8-contact Directional Leads.

Study Design: This study comprises two distinct phases. Phase 1 is a cross-sectional investigation designed to identify the optimal algorithm for patterned stimulation in the VIM region . Phase 2 is a prospective clinical trial focusing on the assessment of safety and efficacy of bilateral VIM-DBS in patients with essential tremor.

Objectives: The primary objective in Phase 2 is to evaluate the safety and effectiveness of bilateral VIM-DBS in individuals with essential tremor. In Phase 1, the investigators seek to explore the impact of the Chronos programming software on tremor patients who have experienced early or late loss of benefits.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Phase 1: 5 to 10 tremor patients already treated with VIM-DBS but not doing well due to early and/or late loss of benefits (i.e. tremor scores ON stimulation identical or greater than before surgery in absence of stimulation).
  • •Phase 2: 10 Essential Tremor patients in need of DBS surgery.
  • •Written and signed Informed Consent.
  • •Age 18 to 85 years old.
  • •Subject must have Essential Tremor, as defined by all the following criteria: (a) isolated tremor syndrome consisting of bilateral action tremor; (b) at least three years duration; and (c) with or without tremor in other locations (e.g., head, voice, or low limbs) [1].
  • •Soft signs (categorizing patients as Essential Tremor-plus) will be allowed and noted in the patient's chart.
  • •Subject must be on stable dose of anti-tremor medication for at least 4 weeks prior to screening.
  • •Subject had no botulinum injection for at least three months prior to screening.
  • •Subject does not have a significant other medical condition biasing the study finding in investigator's opinion.

Exclusion Criteria

  • •Unwilling or inability to follow the procedures specified by the protocol.
  • •Presence of significant psychiatric or cognitive condition likely to compromise the subject's ability to comply with requirements of the study protocol.
  • •Untreated clinically significant depression.
  • •Any current drug or alcohol abuse, as determined by the investigator.
  • •History of suicidal attempt within the last 1 year prior to consent or current active suicidal ideation as determined by the investigator.
  • •Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints.
  • •Any terminal illness with life expectancy of < 12 months.
  • •Participation in any other interventional clinical trial (e.g. drug, device).

Arms & Interventions

Phase 1

Experimental

5 to 10 patients with tremor already treated with VIM-DBS but not doing well because of early or late loss of benefits will be recruited by the PI over a 6 months period. If interested, the potential participants will be screened, informed, and consented by a research coordinator. Before the replacement of their IPG (implantable pulse generator), a baseline measurement will be performed.

Intervention: DBS programing (Other)

Phase 2

Experimental

Ten patients with ET needing DBS-VIM surgery will be recruited and will receive Boston Scientific Genus IPG bilaterally connected to Boston Scientific Cartesia™ 8-contact Directional Leads. The programming will be done in four different settings/periods during the course of 8 months.

Intervention: DBS programing (Other)

Outcomes

Primary Outcomes

Tremor analysis (meter per second squared)

Time Frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

Using accelerometers

Quality of life in Essential Tremor Questionnaire (QUEST)

Time Frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

Range from 0-40, with 0 representing no tremor and 40 representing severe tremor.

Tremor Rating Scale (Part A-B)

Time Frame: Phase 1-Baseline

Range from 0-46. with 0 representing no tremor and 46 representing severe tremor.

Tremor Rating Scale (A-C)

Time Frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

Range from 0-46. with 0 representing no tremor and 46 representing severe tremor.

Speech analysis

Time Frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

automated analysis pipeline in MatLab

Tremor analysis

Time Frame: Phase 1-Baseline

Using accelerometers

Stride length (meter)

Time Frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

Gait Analysis

Tandem gait

Time Frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

Gait Analysis

Base of support (meter)

Time Frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

Gait Analysis

Step length (meter)

Time Frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

Gait Analysis

Single stance time and double stance time (seconds)

Time Frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

Gait Analysis

Posturography (newtons)

Time Frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

Using Proteokinetics Zeno System

Gait speed (meter per second)

Time Frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

Gait Analysis

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Alfonso Fasano
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Alfonso Fasano

MD, PhD, FAAN, Professor

University of Toronto

Study Sites (1)

Loading locations...

Similar Trials